广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第三十四 次会议于 2026 年 3 月 30 日在公司本部会议室以现场结合通讯方式召开，会议通 知已于 2026 年 3 月 27 日以邮件、电话等方式送达了全体董事。会议应参加董事 六名，实际参加董事六名，独立董事吴杰先生、周庆权先生、陶剑虹女士以通讯 方式出席，无委托出席的情况，公司高级管理人员等相关人员列席了本次会议， 会议由董事长王永辉先生主持。本次会议的召开、议事方式和表决程序符合《中 华人民共和国公司法》和《公司章程》对召开董事会的规定，经表决方式通过并 作出如下决议： 一、审议通过了《关于申请借款续期的议案》 会议同意公司向广州农村商业银行股份有限公司黄埔支行申请人民币 55,00 0 万元借款续期，续期不超过两年，用于公司的经营生产发展，借款原有的抵押 等担保相应续期。会议同意授权公司董事长或其指定的授权代表人签署相关合同、 协议等各项法律文件（包括但不限于借款、担保、抵押等）及办理相关借款续期 事宜。 具体内容详见公司在巨潮资讯网披露的《关于申请借款续期的公告》。 表决结果：同意 6 票、反对 0 票、弃权 0 票。 证券代码：30 ...

Group 1: Market Trends and Risks - Roman Shares and Meibang Shares have experienced significant short-term stock price increases, indicating potential market sentiment overheating and irrational speculation risks [1][1] Group 2: Project Investments - Dazhu Laser plans to invest $150 million to establish an overseas operation center in Southeast Asia [1] - Bohai Leasing's subsidiary Avolon intends to sell aircraft leasing assets worth approximately 11.061 billion yuan [1] Group 3: Contract Awards - Fengfan Shares has won a bid for a project with Southern Power Grid valued at approximately 184 million yuan [1] - ST Songfa's subsidiary has signed contracts for the construction of two Capesize bulk carriers [1] Group 4: Financial Performance - Zhongke Shuguang expects a net profit of 2.113 billion yuan for 2025, representing a year-on-year increase of 10.54% [2] - Zhongjiao Technology anticipates a net profit of 156 million yuan for 2025, up 86.13% year-on-year [2] - Sry New Materials forecasts a net profit of 154 million yuan for 2025, reflecting a 35.04% year-on-year growth [2] - Wen's Shares projects a net profit of 5.235 billion yuan for 2025, down 43.59% year-on-year [2] Group 5: Equity Acquisitions - Changxin Bochuang plans to acquire 93.8108% equity in Shanghai Honghui Optical Communication Technology [3] - Shenlian Bio intends to acquire controlling rights of Shizhi Source for 237 million yuan and to develop new business [3] - Tongwei Co. plans to purchase 100% equity of Lihua Qingneng, with stock suspension [3] Group 6: Share Buybacks - Kaipu Cloud plans to repurchase shares worth 50 million to 100 million yuan [3] - Zhongshun Jierou intends to buy back shares worth 60 million to 120 million yuan [3] - Yuanli Co. plans to repurchase shares worth 50 million to 60 million yuan [3] Group 7: Shareholding Changes - Conch Cement plans to increase its A-share holdings by 700 million to 1.4 billion yuan [3] - Fushi Holdings' Song Chunqing intends to reduce holdings by no more than 2% [3] - Zhixin Precision's director Zhang Guojun plans to reduce holdings by no more than 1.8562% [3] - Yashida Optoelectronics' director Lin Xuefeng plans to reduce holdings by no more than 0.976% [3] Group 8: Other Developments - ST Renfu plans to raise 3 billion to 3.5 billion yuan through a private placement to its controlling shareholder, Zhaoshang Biotechnology [4] - ST Xiangxue has received a decision to extend the pre-restructuring period [4] - Kaipu Cloud has terminated a major asset restructuring [4]

Shareholder Reductions - Fushi Holdings' shareholder Song Chunqing plans to reduce holdings by no more than 2% [1] - Yasheng Optoelectronics' director Lin Xuefeng intends to reduce holdings by no more than 0.976% [1] - Ruisheng Intelligent's shareholder Ruihe Sheng has cumulatively reduced 2% of the company's shares [1] - Jingjin Electric's shareholder Chenghui International has already reduced 1.00% of the company's shares [1] - Zhongke Feimiao's shareholder Guotou Chuangye Fund has cumulatively completed a reduction of 0.85% of the company's shares [1] - Saiwu Technology's shareholder Dongyun Chuangtou has cumulatively reduced 4.3468 million shares [1] - Huizhiwei's shareholder GZPA has reduced 4.6684 million shares [1] - Zhixin Precision's director Zhang Guojun plans to reduce holdings by no more than 1.8562% [1] - Hengtong Co., Ltd.'s shareholder Liu Zhendong plans to reduce holdings by no more than 21.4256 million shares [1] - Jingneng Thermal Power's shareholder Zhao Yibo has cumulatively reduced 3.018 million shares [1] - Lanfeng Biochemical's shareholder Hainan Wenqin has reduced 3.5648 million shares [1] - China Nuclear Construction's shareholder China Cinda has reduced 8.0354 million shares [1] - Gaiyang New Energy's shareholder Ningxia Bitai has cumulatively reduced 44.3618 million shares [1] Other Corporate Actions - Kaipu Cloud has terminated a major asset restructuring [1]

Group 1: Key Announcements - Xianggu Jichuang currently holds a 5.8018% stake in Hangju Technology, classified as a financial investment [1] - Meibang Co., Ltd. has seen a short-term continuous rise in stock price, indicating potential market sentiment overheating and irrational speculation risks [1] - Dazhu Laser plans to invest $150 million to establish an overseas operation center in Southeast Asia [1] - Fengfan Co., Ltd. won a bid for a project worth approximately 184 million yuan from the Southern Power Grid [1] - Jialian Biological intends to acquire controlling interest in Shizhi Yuan for 237 million yuan and expand into new business [1] - Jiaokong Technology forecasts a net profit of 156 million yuan for 2025, representing an 86.13% year-on-year increase [1] - Zhongshun Jierou plans to repurchase shares worth between 60 million and 120 million yuan [1] - Zhixin Precision's director Zhang Guojun plans to reduce his stake by no more than 1.8562% [1] - ST Renfu aims to raise 3 to 3.5 billion yuan through a private placement to its controlling shareholder,招商生科 [1] - Kaipu Cloud has terminated a significant asset restructuring [1] Group 2: Performance Highlights - Zhongke Shuguang expects a net profit of 2.113 billion yuan for 2025, a year-on-year increase of 10.54% [2] - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, reflecting a 108.05% year-on-year growth [2] - Jiaokong Technology's net profit for 2025 is projected at 156 million yuan, up 86.13% year-on-year [2] - Sry New Materials anticipates a net profit of 154 million yuan for 2025, a 35.04% increase year-on-year [2] - Wens Foodstuff Group's net profit for 2025 is expected to be 5.235 billion yuan, down 43.59% year-on-year [2] Group 3: Equity Acquisitions - Changxin Bochuang plans to acquire a 93.8108% stake in Shanghai Honghui Guanglian Communication Technology [3] - Shenlian Biological intends to acquire controlling interest in Shizhi Yuan for 237 million yuan and expand into new business [3] - Tongwei Co., Ltd. plans to purchase 100% equity of Lihua Qingneng, with stock suspension [3] Group 4: Share Buybacks - Kaipu Cloud plans to repurchase shares worth between 50 million and 100 million yuan [3] - Zhongshun Jierou intends to repurchase shares worth between 60 million and 120 million yuan [3] - Yuanli Co., Ltd. plans to repurchase shares worth between 50 million and 60 million yuan [3] Group 5: Shareholding Changes - Conch Cement plans to increase its A-share holdings by 700 million to 1.4 billion yuan [3] - Fushi Holdings' Song Chunqing plans to reduce his stake by no more than 2% [3] - Zhixin Precision's director Zhang Guojun plans to reduce his stake by no more than 1.8562% [3] - Yashiguangdian's director Lin Xuefeng plans to reduce his stake by no more than 0.976% [3] Group 6: Other Developments - ST Renfu (rights protection) plans to raise 3 to 3.5 billion yuan through a private placement to its controlling shareholder [3] - ST Xiangxue (rights protection) received a decision to extend the pre-restructuring period [3] - Kaipu Cloud has terminated a significant asset restructuring [3]

证券代码:300147 证券简称:ST 香雪 公告编号:2026—005 广州市香雪制药股份有限公司 关于收到延长预重整期间决定书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、广州中院延长公司预重整期间情况 2026 年 2 月 24 日，广州市香雪制药股份有限公司（以下简称"公司"）收 到广州市中级人民法院（以下简称"广州中院"）送达的（2025）粤 01 破申 54 -3 号《决定书》，主要内容如下： 经审查，本院同意广州市香雪制药股份有限公司预重整期间延长至 2026 年 4 月 11 日。 二、公司预重整进展情况 1、2025 年 1 月 27 日，公司收到债权人广东景龙建设集团有限公司（以下 简称"景龙建设"）送达的《告知函》，其以公司未履行生效法律文书、不能清 偿到期债务，明显缺乏清偿能力，但具有重整价值及重整的可行性为由，向广州 中院申请对公司进行预重整。具体内容详见公司于 2025 年 2 月 6 日在巨潮网披 露的《关于被债权人申请预重整的提示性公告》（公告编号：2025-002）。 2025 年 2 月 12 日，广州中院就公 ...

Recent Events - The company held its 33rd meeting of the 9th Board of Directors on February 13, 2026, to review a proposal for a loan restructuring, seeking up to 369 million yuan from Guangdong Nanhai Rural Commercial Bank for operational development, with guarantees from subsidiaries and actual controllers. This move is related to the ongoing pre-restructuring process, which has been extended twice, with the latest extension until January 11, 2026, but the transition to formal restructuring remains uncertain pending court decisions [2]. Company Status - The company is facing significant litigation pressure, with a total litigation amount of approximately 92.27 million yuan as of February 8, 2026, accounting for 8.78% of the latest audited net assets. This includes a contract dispute with Guangzhou Wanbo Jiacheng Venture Capital of 20.92 million yuan and a financial loan dispute with a bank of 44.96 million yuan, with some cases still unresolved, and the impact on profits is yet to be assessed [3]. Performance and Operations - The company expects a net loss attributable to shareholders of 635 million to 934 million yuan for the full year of 2025, primarily due to high financial expenses, asset impairments, and litigation costs. Given the continuous losses, there is a need to be cautious about the risk of delisting [4].

Group 1 - The company ST Xiangxue (300147.SZ) announced a loan restructuring application for up to RMB 369 million from Guangdong Nanhai Rural Commercial Bank to support its operational development [1] - The loan restructuring will be guaranteed by the company's subsidiary Guangzhou Xianglan Health Industry Co., Ltd., and actual controllers Wang Yonghui and Chen Shumei, with company assets including factories, land use rights, and construction projects used as collateral [1] - The subsidiary Guangzhou Xianglan Health Industry Co., Ltd. has completed internal review procedures to agree to continue providing guarantees for the restructuring loan [1] Group 2 - The subsidiary Guangdong Gaoxun Medical Catheter Co., Ltd. applied for a loan restructuring of up to RMB 68.1 million from Guangdong Nanhai Rural Commercial Bank for its operational development [2] - Similar to the previous loan, this restructuring will also be guaranteed by the company, Guangzhou Xianglan Health Industry Co., Ltd., and the actual controllers, with company assets used as collateral [2] - The subsidiary has also completed internal review procedures to agree to continue providing guarantees for the restructuring loan [2]

广州市香雪制药股份有限公司 关于申请借款重组的公告 证券代码:300147 证券简称: ST 香雪 公告编号:2026-004 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、借款重组概述 （一）根据业务发展需要，广州市香雪制药股份有限公司（以下简称"公司"） 向广东南海农村商业银行股份有限公司申请不超过人民币 36,930 万元借款重组， 期限一年，用于公司的经营生产发展。本次借款重组由公司子公司广州香岚健康 产业有限公司、实际控制人王永辉、陈淑梅提供连带责任担保，由公司及广州香 岚健康产业有限公司所持有的厂房、土地使用权、在建工程予以抵押担保。本次 担保事项属于以公司全资子公司及公司自身的资产为公司提供担保，全资子公司 广州香岚健康产业有限公司已履行了内部审议程序同意继续为重组借款提供担 保。 （二）根据业务发展需要，公司子公司广东高迅医用导管有限公司（以下简 称"高迅公司"）向广东南海农村商业银行股份有限公司申请不超过人民币 6,810 万元借款重组，期限一年，用于高迅公司的经营生产发展。本次借款重组由公司、 广州香岚健康产业有限公司、实际控制人王永 ...

根据业务发展需要，会议同意公司向广东南海农村商业银行股份有限公司申 请不超过人民币 36,930 万元借款重组，同意公司子公司广东高迅医用导管有限 公司向广东南海农村商业银行股份有限公司申请不超过人民币 6,810 万元借款 重组，期限均为一年，用于经营生产发展，上述借款原有的抵押担保相应延期。 同意授权公司董事长或其指定的授权代表人签署相关合同、协议等各项法律文件 （包括但不限于借款、担保、抵押等）及办理相关借款展期事宜。 第九届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）第九届董事会第三十三 次会议于 2026 年 2 月 13 日在公司本部会议室以现场结合通讯方式召开，会议通 知已于 2026 年 2 月 10 日以邮件等方式送达了全体董事。会议应参加董事六名， 实际参加董事六名，独立董事吴杰先生、周庆权先生、陶剑虹女士以通讯方式出 席，无委托出席的情况，公司高级管理人员等相关人员列席了本次会议，会议由 董事长王永辉先生主持。本次会议的召开、议事方式和表决程序符合《中华人民 ...

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (ST Xiangxue, 300147.SZ) has disclosed that it and its subsidiaries have been involved in lawsuits with a total amount of approximately 92.27 million yuan over the past twelve months, which accounts for 8.78% of the latest audited net assets [1] Group 1 - The total amount involved in lawsuits is approximately 92.27 million yuan [1] - The amount related to a contract dispute with Guangzhou Wanbo Jiacheng Venture Capital Partnership is 20.92 million yuan [1] - The financial loan dispute with a certain bank involves an amount of 44.96 million yuan [1] Group 2 - Some of the cases are still under trial or unresolved, and the specific impact will depend on the audited financial report [1]